Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-Guided Sunitinib and Regorafenib for GIST
NCT05366816Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib and regorafenib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by University of Miami. Primary endpoint: Overall Response at 12 months. Started Oct 2023; status: recruiting.
02
Drugs
sunitinibregorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05366816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366816.